Journal of clinical gastroenterology
-
J. Clin. Gastroenterol. · Apr 2011
Randomized Controlled Trial Multicenter Study Comparative StudyA new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial.
To investigate the efficacy and safety of a new proton pump inhibitor (PPI), ilaprazole (IY-81149) in the treatment of duodenal ulcers and provide some characteristics of the dose-response relationship for later studies. ⋯ Ilaprazole is as tolerable, safe, and efficacious as omeprazole in the treatment of duodenal ulcers, especially at a lower dose (10 mg/d ilaprazole vs. 20 mg/d omeprazole). (ClinicalTrials.gov ID: NCT00953381).
-
J. Clin. Gastroenterol. · Apr 2011
ReviewStool DNA screening for colorectal cancer: opportunities to improve value with next generation tests.
General adoption of the screening tests for colorectal cancer (CRC) by patients, health care professionals, medical centers, and third party payers rests on a favorable assessment of value. Reported cost-effectiveness estimates of stool DNA testing for CRC screening incorporated performance assumptions based on data from the first generation tests. Given the substantial technical advances in stool DNA testing that have occurred subsequently, estimates of value will need to be revisited. This review briefly examines the early cost-effectiveness estimates for stool DNA screening and looks ahead at how the next generation tests might improve such value estimates for CRC screening.
-
J. Clin. Gastroenterol. · Apr 2011
Natural history of asymptomatic small gastric subepithelial tumors.
To assess the natural history of gastric subepithelial tumors (SETs) of ≤30 mm in size and to determine their optimal management. ⋯ Only 8.5% of gastric SETs of ≤30 mm in size showed significant changes at a median 24 months. SETs of 10 to 30 mm in size grew significantly more rapidly than SETs <10 mm.